1	Incidence.	symptoms and	l medical c	care for influenza	virus and r	espiratory s	svncvtial v	virus
							,,,	

2 illnesses among older adults in Eastern China: Findings from the China Ageing

3	Respiratory	Infections	Study ((CARES),	2015-2017
-				/)	

- 4 Nancy H. L. Leung^{1,2*}, Hongjun Zhang^{3*}, Jun Zhang^{4*}, Fenyang Tang⁵, Lin Luan⁴, Benfeng
- 5 Zheng⁴, Guoqing Chen³, Changcheng Li³, Qigang Dai⁵, Cuiling Xu^{1,6}, Yuyun Chen¹, Daniel K.
- 6 W. Chu¹, Ying Song⁷, Ran Zhang⁷, Lindsay Kim^{7,8}, Rachael Wendlandt⁹, Huachen Zhu^{1,10}, Fiona
- 7 Havers^{7,8}, Hongjie Yu¹¹, Pat Shifflett⁹, Carolyn M. Greene⁷, Benjamin J. Cowling^{1,2∧†}, Mark G.
- 8 Thompson^{7†}, A. Danielle Iuliano^{7,8†} on behalf of the China Ageing Respiratory Infections Study
- 9 (CARES) investigators#
- 10

11 * joint first authors, ^ corresponding author, † joint senior authors

12

13 Affiliations:

- 14 1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
- 15 Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
- 16 Special Administrative Region, China.
- 17 2. Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, New
- 18 Territories, Hong Kong Special Administrative Region, China.
- 19 3. Yancheng Center for Disease Prevention and Control, Yancheng, China.
- 20 4. Suzhou Center for Disease Prevention and Control, Suzhou, China.
- 21 5. Jiangsu Provincial Center for Disease Prevention and Control, Nanjing, China.
- 22 6. Chinese National Influenza Center, National Institute for Viral Disease Control and
- 23 Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

- 24 7. Centers for Disease Control and Prevention, Atlanta, GA, USA.
- 25 8. US Public Health Service, Rockville, MD, USA.
- 26 9. Abt Associates, Cambridge, MA, USA.
- 27 10. Joint Institute of Virology (Shantou University / The University of Hong Kong) &
- 28 Guangdong-Hongkong Joint Laboratory of Emerging Infectious Diseases, Shantou University,
- 29 Shantou, China.
- 30 11. School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry
- 31 of Education, Shanghai, China.
- 32

33 Corresponding author:

- 34 Prof. Benjamin J. Cowling, School of Public Health, The University of Hong Kong, 7 Sassoon
- 35 Road, Pokfulam, Hong Kong Special Administrative Region, China.
- 36 Tel: +852 3917 6711. Email: bcowling@hku.hk.
- 37
- 38 # The CARES investigators are listed in the Acknowledgments
- 39
- 40 Word count (Abstract): 250 (limit: 250)
- 41 Word count (Main text): 3492, 30 refs (limit: 3500, 30 refs)
- 42
- 43 Running head: Influenza and RSV in older adults in Eastern China

- 45 Key words: influenza virus; respiratory syncytial virus; older adults; incidence; hospitalization;
- 46 cohort studies; disease burden.

47 SUMMARY (250 words)

- 48 Introduction: Few studies have examined the incidence of virologic-confirmed influenza virus
- 49 and respiratory syncytial virus (RSV) infections in community-dwelling older adults.
- 50 Methods: We enrolled adults aged 60–89 years in Jiangsu Province, China and followed them
- 51 weekly from December 2015–September 2017 to identify acute respiratory illnesses (ARI),
- 52 collect illness information and respiratory specimens for laboratory testing.
- 53 **Results:** 1,527 adults were enrolled, 0.4% reported ever receiving influenza vaccination. 95
- 54 PCR-confirmed influenza ARIs and 22 RSV ARIs were identified, among whom 4–5% required
- 55 hospitalization. One death associated with RSV ARI while none for influenza ARIs was
- 56 observed. From December 2015-August 2016, the cumulative incidences of influenza and RSV
- 57 ARIs were 0.8% (95% CI:0.3-1.4) and 0.5% (95% CI:0.1-1.0), respectively. From September
- 58 2016-August 2017, the cumulative incidences were 6.1% (95% CI:4.7–7.7) and 1.0% (95%
- 59 CI:0.5-1.6); the influenza and RSV ARI-associated hospitalization incidences were 0.3% (95%)
- 60 CI:0-0.8) and 0.1% (95% CI:0-0.2). Feverishness was more common in influenza (55%) than
- 61 RSV ARIs (30%, p=0.03). Influenza (12.5 days, p=0.02) and RSV ARI symptoms (14.1 days,
- 62 p=0.15) lasted longer compared to PCR-negative/other ARIs (11.0 days). Antibiotic use was
- 63 more common for influenza (65%, p=0.02) and RSV (70%, p=0.04) ARIs than other ARIs

64 (51%).

Conclusions: We observed a higher incidence of influenza relative to RSV infections among
 community-dwelling older adults compared to prior studies. Our findings suggest older adults
 may benefit from receiving influenza and RSV vaccines to reduce the occurrence of illnesses.

69 INTRODUCTION

Respiratory virus infections like influenza virus and respiratory syncytial virus (RSV) are major 70 71 causes of acute hospitalizations and deaths. In temperate climates infections occur mainly during 72 winter, where in tropical and subtropical climates infections may occur year-round.¹ In older 73 adults, while the potential severity of influenza illness is commonly known,² studies suggested RSV severity may be similar or greater than influenza.³ The World Health Organization 74 75 recommends prioritizing older adults to receive influenza vaccination but uptake remains low in 76 many locations.⁴ More recently RSV vaccines for older adults were approved in some countries.⁵ 77 78 Vaccination polices require knowledge of influenza and RSV disease burden. Community-based 79 cohort studies⁶⁻¹⁰ can actively identify respiratory illnesses not captured by routine health 80 systems. However, most of these studies have been conducted in households with children^{6,11-13} and in high-income countries.¹⁴ Fewer were among older adults^{15,16} including those aged >80 81 years, a group vulnerable to severe complications from these infections,¹⁴ and in low-and-middle 82 83 income countries.^{12,16-18} To address this gap, we established a community cohort of older adults 84 in Jiangsu Province, China to characterize the incidence, symptom profiles, and medical care of PCR-confirmed influenza virus and RSV illnesses from December 2015-September 2017.¹⁹ 85 86

87 METHODS

88 Study design

We monitored respiratory illnesses in a prospective longitudinal cohort of older adults aged 60–
89 years in Jiangsu Province, China (Figure 1A) from December 2015–September 2017 (Figure
1B), A detailed cohort description was previously published.¹⁹ In brief, we screened and enrolled

92 older adults in New District and Xiangcheng in Suzhou and Economic Development Zone (EDZ) 93 and Tinghu in Yancheng, representing urban and semi-urban areas with different socio-economic 94 development levels in eastern China. We recruited older adults in three age groups (60–69, 70– 95 79, and 80–89 years old) with oversampling among those aged 80–89 years. At enrolment, we 96 collected information on demographics, household size, influenza vaccination history, smoking 97 status, medical history, cognitive functioning, and self-rated health and functioning.²⁰ For 98 cognitive functioning, two measures were used: the Mini-Cog (3-item recall) and Standardized 99 Mini-Mental State Examination (SMMSE).^{21,22}

100

101 We conducted year-round active surveillance for acute respiratory illness (ARI) (Appendix 102 **Methods**) because influenza viruses are known to circulate beyond the typical winter months in 103 eastern China, and we expect RSV to circulate mostly in winter seasons.^{1,23} During weekly 104 telephone calls, we asked if the participant was experiencing respiratory symptoms. Illness 105 episodes with onset ≥ 14 days apart were considered separate episodes. Home visits were 106 arranged for new ARI episodes to collect respiratory specimens (combined mid-turbinate and 107 oropharyngeal swabs) within 7 days of symptom onset for laboratory confirmation of infections; 108 study staff also administered an acute illness questionnaire that recorded illness symptoms and 109 whether medical care was sought. Ten days after illness onset, a follow-up questionnaire on 110 illness outcome was completed by telephone. Respiratory specimens were placed in coolers at 2-111 8°C and transported to the Suzhou Center for Disease Prevention and Control (CDC) or 112 Yancheng CDC laboratories within 24 hours of collection. Specimens were then stored at -80°C 113 until testing.¹⁹

115 *Ethical approval*

- 116 Written informed consent was obtained from participants. The study was approved by the
- 117 Institutional Review Board of the University of Hong Kong (UW15 404), the Institutional
- 118 Review Board of Abt Associates (Abt IRB # 0837) upon which United States CDC relied, and
- the Ethics Committee of Jiangsu Provincial CDC (JSJK2015-B013-02).

120

121 Laboratory testing

- 122 Respiratory specimens were tested for influenza viruses and RSV by real-time reverse
- 123 transcription-polymerase chain reaction (PCR) using United States CDC primers, probes,

124 reagents, and protocols.¹⁹

125

126 Primary outcomes and statistical analyses

127 We measured the cumulative incidence of symptomatic PCR-confirmed influenza virus and RSV 128 infections using the following illness definitions and outcomes: ARI, influenza-like illness (ILI), 129 medically attended ARI, ARI-associated hospitalization, and ARI-associated death (Appendix 130 **Table 1**). An ARI was defined as ≥ 2 of the following signs or symptoms with onset in the past 7 131 days: fever (self-reported feverishness, chills, or temperature $\geq 37.8^{\circ}$ C), cough, sore throat, runny 132 nose or nasal congestion, headache, myalgia (body or muscle aches and pain), or worsened 133 shortness of breath. To compare with prior studies, we examined a subset of ARI as ILI defined 134 as self-reported fever $\ge 37.8^{\circ}$ C plus cough with onset in the past 7 days. A medically attended 135 ARI was defined as an ARI with a self-reported visit to a doctor or other medical professional 136 during the acute illness, including visits to outpatient medical clinic/offices, emergency rooms, 137 or hospitals. An ARI-associated hospitalization was defined as a self-reported hospitalization

(i.e., overnight stay in hospital) during the ARI episode. An ARI-associated death was a death
that occurred within 14 days of respiratory illness onset. A PCR-positive respiratory specimen
indicated a virologic-confirmed influenza virus or RSV infection.

141

142 We defined the cumulative incidence of influenza or RSV ARI as the proportion of participants 143 with PCR-confirmed influenza virus or RSV infections among participants enrolled at the start of 144 each study year. Study Year 1 was a partial season capturing information from 27 December 145 2015 through 3 September 2016, and Year 2 was a complete season from 4 September 2016 146 through 2 September 2017. From previous studies, we anticipated an annual cumulative incidence of influenza ARI of 2–4% in older adults.^{12,17} A sample size of 1,500 participants 147 148 permitted estimating a cumulative incidence of influenza ARI of 2% with $\pm 0.7\%$ margin of 149 error.¹⁹ We estimated the cumulative and weekly incidence for each age group, and calculated 150 all-age estimates weighted with the population age and sex structure of Jiangsu Province 151 (Appendix Figure 1). We estimated 95% confidence intervals (95% CIs) for the cumulative and 152 weekly incidence using a bootstrap with 2,000 resamples.²⁴ If there were no illness outcomes 153 observed during a surveillance week, the point estimate and uncertainty for the true incidence 154 was represented as 0 (0, 3/n) where n was the number of participants followed.²⁴

155

156 Subjective severity of illness was measured in three ways using previously published

157 methods.^{25,26} First, participants rated the severity of each symptom as absent, mild, moderate, or

severe (0–3, respectively), and then a mean symptom severity score (1-3) was calculated.

159 Second, self-rated overall health during the illness was rated from 0 (worst) to 100 (best health

160 state). Third, the ability to complete regular activities were rated from 0% (unable) to 100% (able

161	to do all activities and responsibilities). Illness duration was defined as the number of days
162	between dates for ARI symptoms onset and resolution with both dates inclusive. We compared
163	illness characteristics of ARI episodes with PCR-confirmed influenza ('influenza ARI') or RSV
164	infections ('RSV ARI'), with ARI episodes that were influenza and RSV PCR-negative
165	(henceforth PCR-negatives). We used Student's t-test for comparison of severity scores and
166	durations, and Fisher's exact test for cognitive functioning, symptoms and medical care.
167	Analyses were done using R version 4.3.1 (R Foundation for Statistical Computing, Vienna,
168	Austria), and geospatial data from the Global Administrative Areas (GADM) database version
169	2.8. ²⁷
170	
171	Role of the funding source
172	This study was financially supported by the US Centers for Disease Control and Prevention
173	through a contract (HHSD2002013M53890B: 200-2014-F-60406 to Abt Associates, Inc.), and a
174	cooperative agreement (grant no. 1U01IP001064).
175	
176	RESULTS
177	We approached 2,280 older adults and screened 1,914 (84%). Of those, 1,573/1,914 (82%) met
178	inclusion criteria, 1,532/1,573 (97%) were enrolled, and 1,527/1,532 (97%) initiated acute
179	respiratory illness surveillance. ¹⁹ As planned, distribution across participant age groups was
180	similar: 60-69 years (n=547, 36%), 70-79 years (515, 34%), and 80–89 years (465, 30%) (Table
181	1). Most participants lived in urban (24%) or semi-urban (43%) areas and had no formal
182	education (51%) or only attended primary school (34%). At enrollment, most participants
183	described overall health status as excellent, very good, or good (59%) compared with fair or poor

184 (40%). Sixty-nine percent of participants self-reported ≥ 1 chronic health condition and 15% 185 reported hospitalization in the past two years. Assessing cognitive function, almost all 186 participants (98%) recalled three items, with the remaining recalling 1-2 items and having the 187 ability to complete a clock drawing test. 188 189 From 27 December 2015—2 September 2017, 1,337/1,527 (88%) participants completed active 190 surveillance follow-up. Among the 190 (12%) lost to follow-up, 84 (44%) died, 7 (4%) withdrew 191 due to deteriorating health and 81 (43%) withdrew for other reasons (Appendix Table 2). 192 Approximately 30% of follow-up contacts to participants were through a proxy who had daily 193 interaction with the participant. From 29,551 and 29,822 successful contact person-weeks 194 reported from New District and Xiangcheng in Suzhou, and 20,036 and 41,075 person-weeks 195 from EDZ and Tinghu in Yancheng respectively (Appendix Tables 3-6), were identified 1,043 196 episodes of acute illness, of which 898 (86%) reported by 522 participants met the ARI 197 definition. We collected respiratory specimens for 840 (94%) ARI episodes, 95 (11%) were 198 PCR-confirmed influenza virus infections ("influenza ARI") and 22 (3%) were RSV infections 199 ("RSV ARI"), including 4 co-infections. Two participants (0.1%) had two separate influenza 200 ARIs (Table 2). We identified 56 (59%) influenza and 16 (73%) RSV ARIs from December— 201 February, compared with 12 (13%) and none during June—September (Figure 1C). The 202 temporal pattern of influenza detections in our cohort was consistent with community 203 surveillance data over the same period (Appendix Figure 2). There were 26 (1.7%) ARI-204 associated hospitalizations; four were influenza ARIs and one was an RSV ARI (Table 2). One 205 death associated with RSV ARI was observed and zero for influenza ARI (Table 2). 206

207	Of the 95 influenza virus infections, 86 were influenza A, 8 were influenza B, and one was a co-
208	infection with influenza A and B viruses. Influenza A subtyping was completed for 63
209	specimens; 9 (14%) were A(H1N1) and 54 (86%) were A(H3N2). Twenty-three specimens were
210	not subtyped due to high PCR cycle thresholds. Four influenza B viruses were B/Victoria, three
211	were B/Yamagata, and two were untyped. The most commonly detected virus in Year 1 was
212	A(H1N1) and in Year 2 was A(H3N2) (Appendix Figure 2).
213	
214	We estimated the cumulative incidence (Table 3) and incidence rate (Appendix Table 7) by age
215	group, and weighted overall estimate, of PCR-confirmed influenza ARI or RSV ARI in each
216	study year. In Year 1, the overall age-weighted incidence of influenza ARI among older adults
217	\geq 60 years was 0.8% (95% CI:0.3–1.4), and that of influenza ARI-associated hospitalizations
218	was 0.1% (95% CI:0-0.3). In Year 2, the age-weighted influenza ARI and influenza ARI-
219	associated hospitalization incidences were $6 \cdot 1\%$ (95% CI:4 $\cdot 7$ –7 $\cdot 7$) and $0 \cdot 3\%$ (95% CI:0–0 $\cdot 8$)
220	respectively. For RSV, in Year 1 the overall age-weighted incidence of RSV ARI was 0.5%
221	(95% CI: $0.1-1.0$), with no hospitalizations observed. In Year 2, the age-weighted RSV ARI and
222	RSV ARI-associated incidences were 1.0% (95% CI:0.5-1.6) and 0.1% (95% 0-0.2)
223	respectively. Significant differences between age groups were not observed (Appendix Figure
224	3).
225	
226	Acute illness surveys were completed for 822 (92%) ARI episodes from 487 participants.
227	Comparing ARIs of different virus actiologies (Table 4, Figure 2, Appendix Figure 4),

- subjective feverishness was more common in influenza ARI (55%) compared to RSV ARI (30%,
- 229 p=0.03) or PCR-negatives (44%, p=0.04). Influenza ARIs met the ILI case definition (24%,

230	p=0.04) significantly more often than PCR-negative ARIs (16%), but not statistically different
231	for RSV ARIs (15%). The sensitivity of the ILI case definition for influenza ARI detection was
232	24% (95% CI: 15%, 34%) and 15% (95% CI: 3%, 38%) for RSV ARIs; the specificity was 83%
233	(95% CI: 81%, 87%) and 83% (95% CI: 80%, 86%), respectively. Older adults with influenza
234	ARI reported higher symptom severity scores for subjective fever (Appendix Table 8) and
235	worsened shortness of breath (Appendix Table 9). There were no differences in symptom
236	severity scores by upper respiratory, lower respiratory, or systemic symptom categories. The
237	mean ratings for overall health or ability to do normal activities during the illness were also
238	similar across aetiologies (Table 4). Illness duration for an influenza ARI (12.5 days, 95% CI:
239	11.4, 13.8) was similar to RSV ARI (14.1 days ,95% CI: 10.9, 18.2), but statistically longer
240	(p=0.02) than PCR-negative ARIs (11.0 days, 95% CI: 10.7, 11.3). The number of days spent in
241	bed for influenza ARI (1·2 days, 95% CI: 0·8, 1·7) was also similar to RSV ARI (1·4 days, 95%
242	CI: 0.5, 2.4), but statistically more (p=0.04) than PCR-negative ARIs (0.7 days, 95% CI: 0.6,
243	0.8).

244

245 Participants sought medical attention in 67% (549/822) of ARI episodes (Table 4). Ambulatory 246 care (outpatient care or visit to an emergency room) was common for both influenza and RSV 247 ARIs, with outpatient care statistically more likely for influenza ARI (80%) compared to RSV 248 ARI (50%, p=0.01) or PCR-negative ARI (62%, p \leq 0.001). Participants with influenza ARIs 249 (4.3%, p=0.28) and RSV ARIs (5.0%, p=0.32) were hospitalized more frequently than those 250 with PCR-negative ARIs (2.4%) although the difference was not significant. ARI episodes were classified by the highest level of care obtained, the level of care differed significantly by age 251 252 groups for influenza ARI (p=0.05) and PCR-negative ARI (p=0.03) (Appendix Table 10), with

a trend of less hospitalizations in older age groups for influenza ARI and a reverse trend for
PCR-negative ARI (Appendix Figure 5).

255

Among all ARIs, 71% reported using any medication, with significantly higher use among

257 influenza ARI (84%) than other ARI (Table 4). Antibiotic use was reported in 53% of all ARI

episodes, with significantly higher use among influenza ARIs (65%) and RSV ARIs (70%) than

259 PCR-negative ARIs (51%).

260

261 **DISCUSSION**

262 We estimated the incidence of influenza and RSV ARI, described symptom profiles, and medical 263 care seeking behavior in >1,500 older adults in eastern China between 2015–2017. This was one 264 of the largest prospective observational studies to actively identify laboratory-confirmed 265 influenza and RSV illnesses in older adults. We observed a higher incidence (6.1%) of PCR-266 confirmed influenza ARI in 2016–17 (study year 2) when circulation of influenza A(H3N2) virus 267 predominated; and a lower incidence (0.8%) in 2015–16 (year 1), based on only a partial study 268 year of active surveillance when circulation of influenza A(H1N1) virus predominated. We 269 estimated PCR-confirmed RSV ARI incidence ranged from 0.5-1.0% in both study years. While 270 our study was not powered to estimate hospitalization incidences, our findings suggested 271 cumulative incidences of 0.1-0.3% and 0-0.1% for hospitalization during acute influenza ARI 272 and RSV ARI, respectively in community-dwelling older adults ≥ 60 years; and no hospitalizations were observed in those \geq 80 years for either influenza or RSV ARI in our cohort. 273 274 Understanding the effect of influenza virus and RSV infections on older adults provides an 275 evidence base to inform prevention and control measures, including vaccine programs.

277	Community-based studies of influenza incidence have mostly focused on all ages ^{12,17,18} and few
278	focus on older adults specifically. ¹⁵ Tinoco et al. identified ILI, defined as fever or feverishness
279	plus cough or sore throat, by three times weekly home visits in about 500 older adults \geq 65 years
280	old from four sites in Peru between 2009–15, with reported influenza vaccination coverage of 26
281	per 100 person-years. ¹⁷ Prasert et al. identified ARI, defined as new onset of cough or worsening
282	of chronic cough regardless of fever, by weekly calls or home visits in about 1,500 unvaccinated
283	adults ≥65 years in a prospective observational cohort on influenza vaccine effectiveness in
284	Thailand between 2015–17. ¹⁵ Cohen et al. identified infection by nasopharyngeal sampling twice
285	weekly irrespective of symptoms in about 50 older adults ≥65 years (among 1116 participants of
286	all ages from 225 households with almost no influenza vaccination) in South Africa between
287	2016–18.18 Compared to these unvaccinated populations (except Peru), in our study of 1500
288	older adults ≥ 60 years, the estimated A(H1N1) ARI incidence (of $1 \cdot 3/100$ person-years) in study
289	year 1 (a partial season) was less than the incidence (based on symptomatic and asymptomatic
290	infections combined) estimated in South Africa $(2 \cdot 3/100 \text{ person-years during } 2017-18)^{18}$ and
291	higher than influenza illness in Thailand ($<0.3/100$ person-years in 2015-16 and 2016-17
292	seasons). ¹⁵ In study year 2, our estimated A(H3N2) incidence (of $6.5/100$ person-years) was
293	higher than Peru $(3.6/100 \text{ person-years})^{17}$ and Thailand (<2/100 person-years), ¹⁵ but lower than
294	South Africa (13.6/100 person-seasons during 2017–18). ¹⁸ Thus, our virologic-confirmed
295	influenza incidence estimates fell within the range previously described for community-dwelling
296	older adults, and on the higher end when A(H3N2) viruses predominated. Our study also
297	provided valuable data on influenza ARI-associated hospitalizations in community-dwelling
298	older adults aged ≥80 years, that despite actively identifying ARI we did not observe more

influenza ARI- or RSV ARI- associated (acute) hospitalizations in them than those younger
between 60-79 years old, although our study was underpowered to observe statistical differences
between age groups.

302

303 With RSV vaccines now available for older adults, data on RSV incidence in community-304 dwelling older adults can inform population impact and models evaluating the potential benefits 305 of RSV vaccination programs in older adults, although few of these studies exist, particularly before the COVID-19 pandemic.^{6,8,16,28,29} Prior studies identified RSV illness by passive 306 surveillance only²⁹ or evaluated incidence based on both virologic and serologic confirmed 307 308 infection.⁸ Korsten et al. (RESCEU study) assessed annual RSV community burden in about 500 309 older adults ≥ 60 years old from three cities in Europe between 2017–19 by weekly emails or 310 calls to identify ARI, which was defined as having at least one of the following symptoms: 311 cough, nasal congestion or discharge, wheezing or shortness of breath.²⁸ Our study, with active 312 surveillance in >1,500 older adults, found that 0.5-1% experienced virologic-confirmed RSV 313 ARI, 0.3-0.6% had medically attended RSV ARI, and 0-0.1% had RSV ARI-associated 314 hospitalization during 2015–17 in China. In comparison, Korsten et al. reported higher 315 cumulative incidences of virologic-confirmed RSV ARI (2.1% and 4.9% during 2017-18 and 316 2018-19 October–May seasons respectively) and medically attended RSV ARI (0.8% and 1.4% respectively); and even higher estimates if serologic-confirmed infections.²⁸ Our observed lower 317 318 RSV incidences may be due to differences in surveillance methods, laboratory testing, or true 319 epidemiological variations. Future analyses of our study serum samples¹⁹ could identify 320 additional RSV infections.

321

322	Our study suggested older adults with influenza ARI had longer illnesses than those with PCR-
323	negative ARI, consistent with findings in older adults in RESCEU ²⁸ and other working age
324	adults.26 We also observed influenza ARI were more likely to include fever compared to PCR-
325	negative ARI or RSV ARI. More influenza ARI met the ILI case definition; and while the
326	sensitivity of the ILI definition to detect either influenza (24%) or RSV (15%) ARI was low, it
327	was relatively higher for influenza ARI, consistent with earlier findings. ¹⁰ This finding suggests
328	the ILI case definition is less effective for identifying RSV in older adults. To capture RSV
329	burden in community-dwelling older adults through routine public health surveillance systems, a
330	new syndromic case definition may be needed.
331	
332	Over half of our participants with influenza or RSV ARI sought medical care. We observed
333	influenza ARI were more likely to require ambulatory care compared to PCR-negative ARI or
334	RSV ARI, as also reported by Korsten et al. ²⁸ Influenza vaccine coverage was very low (0.4%)
335	in this population in Jiangsu Province, similar to those in other Chinese cities where influenza
336	vaccines require out-of-pocket payment. Future studies are needed to assess the potential benefit
337	of influenza and RSV vaccination on reducing infections and burden on the healthcare system,
338	and methods that increase influenza vaccine uptake among older adults in China.
339	
340	Antibiotic use in 9% of all ARI and overuse in 31% of influenza ARI was reported in Europe. ²⁸
341	Here, antibiotic use was common in all ARI (53%), particularly for influenza (65%) and RSV
342	(70%) ARI, indicating the broad overuse of antibiotics for non-bacterial infections. Although a
343	decline of antibiotic consumption in health care settings particularly in community care was

reported in Shandong Province from 2012–17,³⁰ our study suggested antibiotic overuse was still

prevalent in the community, and efforts to promote rational use of antibiotics in primary careshould be reinforced.

347

Our study has several limitations. First, there may have been under-detection of illnesses and PCR-confirmed infections, especially in the first study year due to influenza virus circulation before active surveillance began. Second, if a proxy reported on behalf of the participant, some illness episodes may have been missed. However, proxies likely reported most illness episodes as they were required to have daily contact with participants. Finally, we evaluated symptoms and severity within four days of reported illness, potentially missing later-developing symptoms.

354

355 Despite these limitations, our study has several important public health implications. We found a 356 higher incidence of PCR-confirmed influenza (mainly from H3N2) in older adults than most 357 previous studies. When the incidence of influenza ARI increased in study year 2, the burden on 358 the healthcare system also increased with more medical care-seeking by older adults, reflecting 359 the effect of seasonal influenza epidemics on healthcare utilisation at the population level. While 360 some cities provide free influenza vaccination for older adults, it is not included in the national 361 immunization program in China and most must pay out-of-pocket. Improving prevention 362 measures such as influenza vaccination in this vulnerable population with extremely low vaccine 363 uptake can reduce infections and healthcare burden. We estimated the incidence of PCR-364 confirmed RSV illness in older adults in both rural and urban settings in China, providing needed 365 data on RSV infections and burden in older Asian populations to inform the need for RSV 366 vaccination programs. We observed widespread use of antibiotics for viral infections. 367

368 **CONTRIBUTORS**

369 All authors meet the International Committee of Medical Journal Editors criteria for authorship. 370 This project is a multi-national collaboration between investigators in the US, Hong Kong, and 371 mainland China, and has required substantial contributions from the co-investigators. In terms of 372 the specific contributions, the study protocol was designed by BJC and MGT and drafted by CX. 373 Substantial input was provided by NHLL, HZ, JZ, FT, LL, BZ, CL, QD, YS, RW, PS, CG, FH, 374 LK, and ADI on the study design in the planning phase in a series of meetings in the US, Hong 375 Kong, and mainland China. The study instruments were prepared by NHLL, CX and RW with 376 input from HZ, JZ, LL, BZ, YC, YS, PS, CG, FH, LK, BJC, MGT and ADI. Study staff training 377 were designed and performed by NHLL, HZ, LL, BZ, QD, CX, YC, YS, RZ, RW, CG and HY. 378 Study activities were managed and organized by HZ, JZ, LL, BZ and YC with oversight by 379 NHLL and BJC. The laboratory tests were developed and performed by GC, DKWC, and HZ. 380 Statistical analyses were done by NHLL. The initial draft of the present manuscript was prepared 381 by NHLL and ADI with input from MGT and BJC, and all authors provided critical review and 382 revision of the text and approved the final version. 383

384 ACKNOWLEDGMENTS

385 CARES investigators also include: Vicky J. Fang, Yi Guan, Chi K. Lam, J. S. Malik Peiris,

386 Yingying Qin (The University of Hong Kong); Min Levine, Brett Whitaker (United States

387 CDC); William Campbell (Abt Associates); Yu Xia, Xuerong Ya, Zefeng Dong (Suzhou CDC);

388 Jinjin Shen, Renjie Jiang, Yao Wang, Yuhong Chen (Yancheng CDC); Yuelong Shu, Luzhao

389 Feng, Jiandong Zheng (China CDC); Weijun Wan (Donggiao Health Center of Huangdai Town,

390 Xiangcheng District, Suzhou); Hongbo Gu (Healthcare Center of Shishan Street Community,

391	New District, Suzhou); Jinhua Shen (Xiangcheng No. 2 People's Hospital, Suzhou); Wenjing
392	Wang (Xiangcheng District Center for Disease Prevention and Control, Suzhou); Risheng Zha
393	(New District Center for Disease Prevention and Control, Suzhou); Liwen Gao (Xiangcheng
394	District Health Commission, Suzhou).
395	
396	The authors would like to thank Eduardo Azziz-Baumgartner, Steve Lindstrom and Jerome
397	Tokars (US CDC) for helpful comments; and Qian Xiong, Hau Chi So, Chi Kin Lam (HKU);
398	Jing Xu (Yancheng CDC); Yuhua Chen, Maogan Wu and Lijuan Wu (Yongfeng Health Center
399	of Tinghu District, Yancheng); Jianhong Wang (Bufeng Health Center of the Economic
400	Development Zone, Yancheng); Ran An (Department of Clinical Laboratory, Yancheng CDC);
401	and other healthcare personnel and colleagues from the Department of Clinical Laboratory,
402	Suzhou CDC; Dongqiao Health Center of Huangdai Town, Xiangcheng District, Suzhou;
403	Healthcare Center of Shishan Street Community, New District, Suzhou; Xiangcheng No. 2
404	People's Hospital, Suzhou; Xiangcheng District CDC, Suzhou; New District CDC, Suzhou; and
405	Xiangcheng District Health Commission, Suzhou for technical support in the study.
406	
407	The findings and conclusions in this report are those of the authors and do not necessarily
408	represent the official position of the U.S. Centers for Disease Control and Prevention or the U.S.
409	Public Health Service.
410	

411 **DECLARATION OF INTERESTS**

412 BJC has consulted for AstraZeneca, Fosun Pharma, GSK, Haleon, Moderna, Novavax, Pfizer,

413 Roche, and Sanofi Pasteur. The authors report no other potential conflicts of interest.

414 REFERENCES

415 1. Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections. 416 Annu Rev Virol 2020; 7(1): 83-101.

- 417 2. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-
- 418 associated respiratory mortality: a modelling study. Lancet 2018; 391(10127): 1285-300.
- 419 3. Ackerson B, Tseng HF, Sy LS, et al. Severe Morbidity and Mortality Associated With
- 420 Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults. Clin Infect
- 421 Dis 2019; 69(2): 197-203.
- 422 4. Palache A, Oriol-Mathieu V, Fino M, Xydia-Charmanta M, Influenza Vaccine Supply

423 task f. Seasonal influenza vaccine dose distribution in 195 countries (2004-2013): Little progress

424 in estimated global vaccination coverage. Vaccine 2015; 33(42): 5598-605.

425 5. Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within

426 reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis 2023; 23(1): e2-e21.

- 427 6. Monto AS, Koopman JS, Bryan ER. The Tecumseh Study of Illness. XIV. Occurrence of 428
- respiratory viruses, 1976-1981. Am J Epidemiol 1986; 124(3): 359-67.
- 429 7. Nicholson KG, Kent J, Hammersley V, Cancio E. Acute viral infections of upper
- 430 respiratory tract in elderly people living in the community: comparative, prospective, population
- 431 based study of disease burden. BMJ 1997; 315(7115): 1060-4.
- 432 8. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus
- 433 infection in elderly and high-risk adults. N Engl J Med 2005; 352(17): 1749-59.
- 434 Xu C, Liu L, Ren B, et al. Incidence of influenza virus infections confirmed by serology 9.
- 435 in children and adult in a suburb community, northern China, 2018-2019 influenza season.
- 436 Influenza Other Respir Viruses 2020; 15(2): 262-9.

- 437 10. Geismar C, Nguyen V, Fragaszy E, et al. Symptom profiles of community cases infected
- 438 by influenza, RSV, rhinovirus, seasonal coronavirus, and SARS-CoV-2 variants of concern. *Sci*439 *Rep* 2023; 13(1).
- 440 11. Hall CE, Cooney MK, Fox JP. The Seattle virus watch. IV. Comparative epidemiologic
- 441 observations of infections with influenza A and B viruses, 1965-1969, in families with young
- 442 children. *Am J Epidemiol* 1973; **98**(5): 365-80.
- 443 12. Fowler KB, Gupta V, Sullender W, et al. Incidence of symptomatic A(H1N1)pdm09
- 444 influenza during the pandemic and post-pandemic periods in a rural Indian community. Int J
- 445 *Infect Dis* 2013; **17**(12): e1182-5.
- 446 13. Cowling BJ, Perera RA, Fang VJ, et al. Incidence of influenza virus infections in children
- in Hong Kong in a 3-year randomized placebo-controlled vaccine study, 2009-2012. *Clin Infect Dis* 2014; **59**(4): 517-24.
- 14. Nguyen-Van-Tam JS, O'Leary M, Martin ET, et al. Burden of respiratory syncytial virus
- 450 infection in older and high-risk adults: a systematic review and meta-analysis of the evidence
- 451 from developed countries. *Eur Respir Rev* 2022; **31**(166).
- 452 15. Prasert K, Patumanond J, Praphasiri P, et al. Effectiveness of trivalent inactivated
- 453 influenza vaccine among community-dwelling older adults in Thailand: A two-year prospective
- 454 cohort study. *Vaccine* 2019; **37**(6): 783-91.
- 455 16. Praphasiri P, Shrestha M, Patumanond J, et al. Underlying cardiopulmonary conditions as
- 456 a risk factor for influenza and respiratory syncytial virus infection among community-dwelling
- 457 adults aged ≥ 65 years in Thailand: Findings from a two-year prospective cohort study.
- 458 *Influenza Other Respir Viruses* 2021; **15**(5): 634-40.

- 459 17. Tinoco YO, Azziz-Baumgartner E, Uyeki TM, et al. Burden of Influenza in 4
- 460 Ecologically Distinct Regions of Peru: Household Active Surveillance of a Community Cohort,
- 461 2009-2015. *Clin Infect Dis* 2017; **65**(9): 1532-41.
- 462 18. Cohen C, Kleynhans J, Moyes J, et al. Asymptomatic transmission and high community
- 463 burden of seasonal influenza in an urban and a rural community in South Africa, 2017-18
- 464 (PHIRST): a population cohort study. *Lancet Glob Health* 2021; **9**(6): e863-e74.
- 465 19. Cowling BJ, Xu C, Tang F, et al. Cohort profile: the China Ageing REespiratory
- 466 infections Study (CARES), a prospective cohort study in older adults in Eastern China. BMJ
- 467 *Open* 2017; **7**(10): e017503.
- 468 20. Idler EL, Benyamini Y. Self-rated health and mortality: a review of twenty-seven
 469 community studies. *J Health Soc Behav* 1997; **38**(1): 21-37.
- 470 21. Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The mini-cog: a cognitive 'vital
- 471 signs' measure for dementia screening in multi-lingual elderly. *Int J Geriatr Psychiatry* 2000;
 472 **15**(11): 1021-7.
- 473 22. Molloy DW, Alemayehu E, Roberts R. Reliability of a Standardized Mini-Mental State
- 474 Examination compared with the traditional Mini-Mental State Examination. *Am J Psychiatry*475 1991; 148(1): 102-5.
- Yu H, Alonso WJ, Feng L, et al. Characterization of regional influenza seasonality
 patterns in China and implications for vaccination strategies: spatio-temporal modeling of
 surveillance data. *PLoS Med* 2013; **10**(11): e1001552.
- 479 24. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting
 480 zero numerators. *JAMA* 1983; **249**(13): 1743-5.

- Sun S, Chen J, Johannesson M, et al. Population health status in China: EQ-5D results, by
 age, sex and socio-economic status, from the National Health Services Survey 2008. *Qual Life Res* 2011; 20(3): 309-20.
- 484 26. Henkle E, Irving SA, Naleway AL, et al. Comparison of laboratory-confirmed influenza
- and noninfluenza acute respiratory illness in healthcare personnel during the 2010-2011
- 486 influenza season. *Infect Control Hosp Epidemiol* 2014; **35**(5): 538-46.
- 487 27. University of California. Global Administrative Areas. 2019. <u>https://gadm.org/</u> (accessed
 488 October 21 2019).
- 489 28. Korsten K, Adriaenssens N, Coenen S, et al. Burden of respiratory syncytial virus
- 490 infection in community-dwelling older adults in Europe (RESCEU): an international prospective
- 491 cohort study. *Eur Respir J* 2021; **57**(4).
- 492 29. Kurai D, Natori M, Yamada M, Zheng R, Saito Y, Takahashi H. Occurrence and disease
- 493 burden of respiratory syncytial virus and other respiratory pathogens in adults aged ≥ 65 years in
- 494 community: A prospective cohort study in Japan. *Influenza Other Respir Viruses* 2021; **16**(2):
- 495 298-307.
- 496 30. Song Y, Han Z, Song K, Zhen T. Antibiotic Consumption Trends in China: Evidence
- 497 From Six-Year Surveillance Sales Records in Shandong Province. *Front Pharmacol* 2020; 11.
- 498

499 Tables

500 Table 1. Demographic characteristics at enrolment of an older adult cohort in the cities of Suzhou and

501 Yancheng, Jiangsu Province, China.

	Age (years)					
	60 - 69	70 - 79	80 - 89	Overall		
	(N=547)	(N=515)	(N=465)	(N=1527)		
	n (%)	n (%)	n (%)	n (%)		
Socio-demographics at enrollment						
Female	293 (54)	277 (54)	280 (60)	850 (56)		
City						
Suzhou	293 (54)	262 (51)	213 (46)	768 (50)		
Yancheng	254 (46)	253 (49)	252 (54)	759 (50)		
Education						
No schooling	200 (37)	245 (48)	330 (71)	775 (51)		
Primary school	242 (44)	179 (35)	98 (21)	519 (34)		
Secondary school or above	105 (19)	91 (18)	37 (8)	233 (15)		
Annual personal income (RMB\$) ¹						
<10,000	297 (54)	372 (72)	353 (76)	1022 (67)		
10,000 to <30,000	174 (32)	84 (16)	60 (13)	318 (21)		
>30,000	49 (9)	35 (7)	25 (5)	109 (7)		
Residence ²						
Urban	126 (23)	135 (26)	113 (24)	374 (24)		
Semi-urban	255 (47)	212 (41)	184 (40)	651 (43)		
Rural	166 (30)	168 (33)	168 (36)	502 (33)		
Household						
Household size, mean (SD)	3.1 (1.6)	2.7 (1.6)	2.6 (1.6)	2.8 (1.6)		
With at least one child <=5y	41 (7)	27 (5)	37 (8)	105 (7)		
Self-reported health-related information at enrolln	<u>ient</u>					
Health status						
Excellent	18 (3)	8 (2)	1 (0)	27 (2)		
Very good	148 (27)	98 (19)	69 (15)	315 (20)		
Good	222 (41)	180 (35)	177 (38)	579 (38)		
Fair	150 (27)	210 (41)	192 (41)	552 (36)		
Poor	9 (2)	19 (4)	26 (6)	54 (4)		
Chronic medical conditions'						
Any	343 (63)	380 (74)	327 (70)	1050 (69)		
Cardiovascular diseases	236 (43)	303 (59)	248 (53)	787 (52)		
Lung diseases	45 (8)	50 (10)	56 (12)	151 (10)		
Diabetes	44 (8)	56 (11)	29 (6)	129 (8)		
Cognitive function – Mini-Cog 3-item recall*						
3 items	533 (97)	507 (98)	457 (98)	1497 (98)		
2 items & Completed clock drawing test	9 (2)	6(1)	6(1)	21 (1)		
1 item & Completed clock drawing test	5(1)	2 (0)	2 (0)	9(1)		
Cognitive function – SMMSE ³						
Normal (30 – 26)	346 (63)	259 (50)	141 (30)	746 (49)		
Mild cognitive impairment $(25 - 20)$	178 (33)	211 (41)	241 (52)	630 (41)		
Moderate cognitive impairment $(19 - 10)$	14 (3)	40 (8)	75 (16)	129 (8)		
Smoking						
Never smoked	330 (60)	327 (63)	323 (69)	980 (64)		
Past smoker	37 (7)	55 (11)	34 (7)	126 (8)		
Current smoker	171 (31)	127 (25)	101 (22)	399 (26)		
Ever received influenza vaccine	1 (0.2)	3 (0.6)	2 (0.4)	6 (0.4)		
Hospitalizations in past two years prior to	57 (10)	93 (18)	86 (18)	236 (15)		

1 US\$1=RMB\$6.7

2 Urban residents are defined as those who live and work in cities/ towns, while rural residents as those who live in villages and farm for their livelihood. Semi-urban refers to areas in a transitional stage towards urbanization.

3 Any chronic medical conditions included cardiovascular diseases, lung diseases, diabetes, kidney disease (excluding kidney stones, bladder

infection or incontinence), live disease (including chronic hepatitis), cancer, depression or anxiety disorder, neurologic disorder (such as epilepsy, any seizure disorder or Parkinson's disease), osteoarthritis, autoimmune disease (such as lupus or rheumatoid arthritis), and any other health problem or condition. In particular, *cardiovascular diseases* included heart problems (such as heart attack, congestive failure, angina, or coronary

- heart disease), hypertension and stroke. Lung diseases included asthma, chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, or any other chronic lung disease.

 - 4 The 3-item recall in the Mini-Cog tool, i.e. the number of words recalled after a several-minute delay and distraction, out of three words. 5 SMMSE: Standardized Mini-Mental State Examination.

514 Table 2. Proportion of participants with acute respiratory illness (ARI), medically attended ARI, ARI-

515 associated hospitalization and death by age group.

	Age (years)			
—	60 - 69	70 - 79	80 - 89	Overall
	(N=547)	(N=515)	(N=465)	(N=1527)
	n (%)	n (%)	n (%)	n (%)
Participants followed ¹				
Participants at start each study year				
Year 1	547 (100)	515 (100)	465 (100)	1527 (100)
Year 2	524 (96)	500 (97)	446 (96)	1470 (96)
Acute respiratory illness and medical care				
Acute respiratory illness (ARI)				
Participants with one ARI episode only	100 (18)	111 (22)	87 (19)	298 (20)
Participants with two or more ARI episodes	86 (16)	86 (17)	52 (11)	224 (15)
Participants with one influenza ARI episode only	34 (6.2)	36 (7.0)	21 (4.5)	91 (6)
Participants with two or more influenza ARI episodes	1 (0.2)	1 (0.2)	0 (0)	2 (0.1)
Participants with one RSV ARI episode only	8 (1.5)	8 (1.6)	6 (1.3)	22 (1.4)
Medically attended ARI ²				
Participants with one medically attended ARI episode only	93 (17)	97 (19)	67 (14)	257 (17)
Participants with two or more medically attended ARI episodes	53 (10)	42 (8)	34 (7)	129 (8)
Participants with one medically attended influenza ARI episode only	33 (6)	30 (5.8)	13 (2.8)	76 (5)
Participants with two or more medically attended influenza ARI episodes	0 (0)	1 (0·2)	0 (0)	1 (0.1)
Participants with one medically attended RSV ARI episode only	5 (0.9)	4 (0.8)	3 (0.6)	12 (0.8)
ARI-associated hospitalization ³				
Participants with one hospitalization only	5 (0.9)	8 (1.6)	13 (2.8)	26 (1.7)
Participants with one hospitalization with influenza ARI only	3 (0.5)	1 (0.2)	0 (0)	4 (0·3)
Participants with one hospitalization with RSV ARI only	0 (0)	1 (0.2)	0 (0)	1 (0.1)
Death within 14 days of ARI symptom onset ⁴				
Deaths	0 (0)	1 (0.2)	0 (0)	1 (0.1)
Deaths with influenza	0 (0)	0 (0)	0 (0)	0 (0)
Deaths with RSV	0 (0)	1 (0.2)	0 (0)	1 (0.1)

1 All participants were enrolled at the start of the study with no replenishment. Year 1: 27 December 2015 - 3 September 2016; Year 2: 4 September 2016 - 2 September 2017.

2 Å medically attended ARI episode is defined as an ARI with a self-reported medical visit to a doctor or other medical professional for this

illness including outpatient medical clinic/offices, emergency rooms or was hospitalized, reported during the acute illness. 3 An ARI-associated hospitalization is defined as an ARI with a self-reported hospitalization, reported during the acute illness.

4 One death during ARI with PCR-confirmed RSV infection but this case was not hospitalized.

523 Table 3. Cumulative incidence of PCR-confirmed influenza ARI, PCR-confirmed RSV ARI, influenza ARI-524 associated hospitalization and RSV ARI-associated hospitalization.

		Cumulative incidence (%	%, 95% confidence interv	al)			
Age (years)	60 - 69	70 - 79	80 - 89	Overall (weighted) ⁶			
<u>Year 1</u> (27 December 2015 - 3 Septem	ber 2016)						
ARI ¹	26.9 (21.9, 32.5)	23.9 (19.4, 28.7)	16.1 (12.5, 20.0)	24.1 (20.7, 27.9)			
ILI ²	3.8 (2.0, 5.9)	3.3 (1.7, 5.2)	3.4(1.7, 5.2)	3.6 (2.4, 5.0)			
PCR-confirmed influenza ARI							
All	$1 \cdot 1 \ (0 \cdot 4, 2 \cdot 0)$	0.4(0, 1.0)	0.4 (0, 1.1)	0.8 (0.3, 1.4)			
Medically attended ³	$1 \cdot 1 \ (0 \cdot 4, 2 \cdot 0)$	0.2(0, 0.6)	0.2(0, 0.6)	0.7(0.2, 1.3)			
Hospitalized ⁴	0.2(0, 0.7)	0 (0, 0.6)	0 (0, 0.6)	0.1(0, 0.3)			
PCR-confirmed RSV ARI							
All	0.5(0, 1.3)	0.6 (0, 1.4)	0.2(0, 0.6)	0.5 (0.1, 1.0)			
Medically attended	0.4(0, 0.9)	0.2 (0, 0.6)	0 (0, 0.6)	0.3 (0, 0.7)			
Hospitalized ⁵	0 (0, 0.5)	0 (0, 0.6)	0 (0, 0.6)	0 (0, 0.2)			
Year 2 (4 September 2016 - 2 Septemb	ber 2017)						
ARI	38.7 (32.4, 45.4)	42.0 (35.8, 48.4)	30.7 (25.3, 37.0)	39.2 (34.6, 44.5)			
ILI	5.7 (3.8, 7.8)	6.8 (4.4, 9.4)	4.9 (2.9, 7.4)	5.9 (4.6, 7.5)			
PCR-confirmed influenza ARI							
All	5.7 (3.8, 7.8)	7.0 (5.0, 9.4)	4.3 (2.5, 6.3)	6.1 (4.7, 7.7)			
Medically attended	5.2 (3.4, 7.1)	6.2 (4.2, 8.6)	2.7(1.3, 4.3)	5.3 (4.1, 6.9)			
Hospitalized	0.4(0, 1.0)	0.2 (0, 0.6)	0 (0, 0.7)	0.3 (0, 0.8)			
PCR-confirmed RSV ARI							
All	1.0(0.2, 1.9)	1.0(0.2, 2.0)	1.1(0.2, 2.2)	1.0 (0.5, 1.6)			
Medically attended	0.6 (0, 1.3)	0.6 (0, 1.4)	0.7 (0, 1.6)	0.6 (0.2, 1.1)			
Hospitalized	0(0, 0.6)	0.2 (0, 0.6)	0(0, 0.7)	0.1(0, 0.2)			

1 Acute respiratory illness (ARI) is defined as an acute onset of ≥ 2 of the following symptoms in the past 7 days: fever (self-reported

feverishness, chills, or temperature ≥37.8°C), cough, sore throat, runny nose or nasal congestion, headache, myalgia (body or muscle aches and pain), or worsened shortness of breath.

2 Influenza-like illness (ILI) is defined as an ARI with measured fever of \geq 37.8°C (self-reported and/or measured by study staff) plus cough. 3 Medically attended ARI is defined as an ARI with a self-reported medical visit to a doctor or other medical professional during the acute illness, including visits to outpatient medical clinic/offices, emergency rooms, or hospitals.

4 ARI-associated hospitalization is defined as a self-reported hospitalization (i.e. staying in the hospital for at least one night as a patient) during an ARI.

5 There were no hospitalizations with PCR-confirmed RSV infections.

6 The cumulative incidence for each age group was unweighted, while the overall cumulative incidence was weighted with the population age

2 and sex structure of Jiangsu province, China.

Table 4. Illness duration, health and functioning, medical care and medication use in PCR-confirmed influenza ARI and RSV ARI.

	Acute respiratory illness (ARI) episodes						
	All ARI	PCR negative ARI	PCR-confirmed ARI	d influenza	PCR-confirmed RSV ARI		PCR- confir med influen za vs. RSV ARI
	(N=822)	(N=705)	(N=93	3)	(N=20)	
	n (%)	n (%)	n (%)	p- value ⁶	n (%)	p- value ⁷	p- value ⁸
Symptom							
Upper respiratory							
Sore throat Runny nose or	500 (61)	430 (61)	55 (59)	0.65	15 (75)	0.31	0.27
nasal congestion	738 (90)	636 (90)	80 (86)	0.27	18 (90)	>0.99	0.69
respiratory							
Cough Worsened	787 (96)	678 (96)	89 (96)	0.77	20 (100)	>0.99	>0.99
shortness of breath	138 (17)	117 (17)	17 (18)	0.76	4 (20)	0.74	>0.99
Systemic							
Fever	490 (60)	413 (59)	63 (68)	0.14	11 (55)	0.61	0.26
Feverish	368 (45)	307 (44)	51 (55)	0.04	6 (30)	0.20	0.03
Chills Measured	317 (39)	266 (38)	43 (46)	0.13	7 (35)	0.80	0.41
temperature ≥ 37·8°C Myalgia (Body or muscle aches	147 (18)	119 (17)	23 (25)	0.04	3 (15)	>0.99	0.33
and pain)	290 (35)	242 (34)	37 (40)	0.48	11 (55)	0.20	0.41
Headache	500 (61)	428 (61)	55 (59)	0.82	14 (70)	0.31	0.28
Case definitions							
Influenza-like illness (ILI) ¹ Illness with any respiratory	139 (17)	114 (16)	22 (24)	0.04	3 (15)	>0.99	0.49
symptoms Illness with any	819 (100)	703 (100)	93 (100)	>0.99	20 (100)	>0.99	-
symptoms Illness with any	793 (96)	683 (97)	88 (95)	0.52	18 (90)	0.41	0.57
symptoms Illness with any	790 (96)	680 (96)	89 (96)	0.56	20 (100)	>0.99	>0.99
symptoms	686 (83)	585 (83)	80 (86)	0.65	17 (85)	0.74	0.71
Cognitive function							
Recalled 3 words	476 (58)	416 (59)	49 (53)	0.30	11 (55)	0.61	>0.99
Medical care							
Medically attended	549 (67)	461 (65)	76 (82)	≤0.01	12 (60)	0.78	0.08
Outpatient	525 (64)	440 (62)	74 (80)	≤0.001	10 (50)	0.28	0.01
room	4 (0.5)	1 (0.1)	1 (1.1)	0.21	1 (5.0)	0.04	0.27
Hospitalized	22 (2.7)	17 (2.4)	4 (4·3)	0.28	1 (5.0)	0.32	0.55

Medication use							
Received any medications	584 (71)	490 (70)	78 (84)	≤ 0·01	16 (80)	0.28	0.71
Antipyretics ¹	157 (19)	125 (18)	28 (30)	0.01	4 (20)	>0.99	0.39
Antibiotics	436 (53)	362 (51)	60 (65)	0.02	14 (70)	0.04	0.37
Other (incl· over-the-counter medication)	179 (22)	149 (21)	27 (29)	0.10	4 (20)	>0.99	0.55

	Mean (95% CI)	Mean (95% CI)	Mean (95% CI)	p- value ³	Mean (95% CI)	p- value ⁴	p- value ⁵
Health and activity							
Self-rated overall							
heath while ill (0-	68 (67, 68)	68 (67, 69)	67 (65, 69)	0.42	67 (62, 72)	0.97	0.83
$100)^{2}$							
Self-rated ability	70 ((0, 70)	70 ((0, 71)	(0)(((-71)))	0.40	(0) $((2)$ (74)	0.94	0.04
$100\%)^3$	/0 (69, /0)	/0 (69, /1)	09 (00, 71)	0.40	08 (03, 74)	0.84	0.94
10070)							
Illness duration (da	<u>ys)</u>						
ARI	11.2 (10.9, 11.5)	11.0 (10.7, 11.3)	12.5 (11.4, 13.8)	0.02	14.1 (10.9, 18.2)	0.15	0.63
ILI	10.5 (9.9, 11.1)	10.4 (9.8, 11.0)	10.6 (9.0, 12.3)	0.71	10.3 (7.0, 16.0)	0.76	0.81
Days in bed ⁴	0.8(0.7, 0.9)	0.7(0.6, 0.8)	1.2 (0.8, 1.7)	0.04	1.4(0.5, 2.4)	0.25	0.88
Duration of hospitalization ⁵	7.7 (6.5, 9.0)	7.8 (6.4, 9.2)	8.8 (6.0, 10.0)	0.43	3 (-, -)	-	-

1 Use of antipyretics was only asked from participants who reported a symptom of fever/feverish, those who did not have fever were assumed to have not taken any antipyretics.

2 Self-rated health while ill described how one felt, with 0% and 100% represented respectively the worst and best health state one could imagine.

3 Self-rated ability to function described how the illness had affected one's life and activities, with 0% and 100% represented respectively one

was unable at all, or able to do all, activities and responsibilities as one would normally do.

4 One day in bed was defined as staying in bed for at least half the day.

5 Only one case of hospitalization with PCR-confirmed RSV infection, therefore significant testing cannot be performed.

6 Compared between influenza virus PCR test-positive versus test-negative regardless of RSV PCR test results; p-value ≤0.05 bolded.

7 Compared between RSV PCR test-positive versus test-negative regardless of influenza virus PCR test results; p-value ≤ 0.05 bolded.

8 Compared between influenza virus PCR test-positive versus RSV PCR test-positive; p-value ≤0.05 bolded.

*Number and percent of those who recalled 3 words

552 Figures

553 Figure 1. (A) CARES study sites – Yancheng and Suzhou, Jiangsu province, mainland China. 554 Blue: Jiangsu province; Green: Yancheng city; Pink: Suzhou city. (B) CARES timeline including

screening period, enrollment period, and active surveillance for acute respiratory illnesses (ARI). 555

556 (C) Weekly numbers of influenza and RSV PCR-negative ARI, PCR-confirmed influenza ARI,

557 and PCR-confirmed RSV ARI. Blue: PCR-confirmed influenza ARI; Red: PCR-confirmed RSV

- 558 ARI; Grey: Influenza and RSV PCR-negative ARI; White: ARI but no respiratory specimen
- 559
 - collected.

560

- 561 Figure 2. (A) Proportion of reported symptoms in participants with PCR-confirmed influenza
- ARI (N=93), PCR-confirmed RSV ARI (N=20), or influenza and RSV PCR-negative ARI 562
- (N=708). (B) Mean symptom severity score for reported symptoms and symptom categories 563
- 564 (upper respiratory, lower respiratory, or systemic symptoms) in participants with PCR-confirmed
- influenza ARI, PCR-confirmed RSV ARI, or influenza and RSV PCR-negative ARI. Blue: PCR-565
- 566 confirmed influenza ARI; Red: PCR-confirmed RSV ARI; Grey: Influenza and RSV PCR-
- 567 negative ARI. * p-value ≤ 0.05





- PCR-confirmed RSV ARI
- PCR-confirmed influenza ARI
- Influenza and RSV PCR-negative ARI

Symptoms in influenza ARI (N = 93), RSV ARI (N = 20) or PCR-negative ARI (N = 708)



Proportion of Reported Symptom

В

Α



Symptom severity score



Severity score